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ABSTRACT
Altered regulation of ER stress response has been implicated in a variety of human 
diseases, such as cancer and metabolic diseases. Excessive ER function contributes to 
malignant phenotypes, such as chemoresistance and metastasis. Here we report that 
the tumor suppressor p53 regulates ER function in response to stress. We found that 
loss of p53 function activates the IRE1α/XBP1 pathway to enhance protein folding 
and secretion through upregulation of IRE1α and subsequent activation of its target 
XBP1. We also show that wild-type p53 interacts with synoviolin (SYVN1)/HRD1/
DER3, a transmembrane E3 ubiquitin ligase localized to ER during ER stress and 
removes unfolded proteins by reversing transport to the cytosol from the ER, and 
its interaction stimulates IRE1α degradation. Moreover, IRE1α inhibitor suppressed 
protein secretion, induced cell death in p53-deficient cells, and strongly suppressed 
the formation of tumors by p53-deficient human tumor cells in vivo compared with 
those that expressed wild-type p53. Therefore, our data imply that the IRE1α/XBP1 
pathway serves as a target for therapy of chemoresistant tumors that express mutant 
p53.
INTRODUCTION
Cancer cells induce distinct alterations of 
metabolic pathways, including glycolysis and protein 
synthesis, to survive and proliferate under conditions 
of stress associated with tumor growth such as nutrient 
limitation and anaerobic stress [1-3]. Cancer cells also 
synthesize a large amount of protein to support their 
rapid growth [4]. The endoplasmic reticulum (ER) is a 
specialized intracellular organelle responsible for the 
proper localization, modification, and folding of proteins. 
Metabolic and anaerobic stress induce ER dysfunction and 
the unfolded protein response (UPR). UPR maintains and 
restores ER homeostasis by increasing protein secretion 
through induction of ER chaperons that mediate protein 
refolding and by degrading unfolded proteins. However, 
irreversible ER stress induces cell death to eliminate 
damaged cells. Thus, increasing the function of ER and its 
resistance to ER stress is essential for tumor proliferation 
and survival, and these processes are implicated in the 
enhancement of ER function in diverse types of human 
cancer cells [5, 6].
Three types of ER transmembrane proteins, protein-
kinase/endoribonuclease inositol-requiring enzyme 1 
alpha (IRE1α), protein kinase R-like ER kinase/pancreatic 
eIF2 kinase (PERK), and activating transcription factor 6 
(ATF6) mediate the mammalian ER stress response as 
well as UPR.[5] IRE1α is a key signal transducer that 
maintains ER function. The IRE1α signaling pathway 
induces expression of the transcription factor XBP1(S), 
which is the active form of XBP1 generated by IRE1α-
dependent splicing of XBP1 mRNA. XBP1(S) increases 
the expression of ER chaperons and ER mass, stimulates 
lipid biogenesis, and degrades unfolded proteins to 
enhance the secretory function of ER and to suppress 
ER stress-mediated cell death [7-9]. In particular, gain 
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of secretory function of ER stimulates the production of 
growth factors such as VEGF [10, 11]. Moreover, the 
activated IRE1α/XBP1 pathway plays an essential role in 
resistance and adaptation to ER stress by many types of 
cancer cells [2, 6, 12]. However, the specific regulatory 
mechanism of activation of the IRE1α/XBP1 pathway in 
cancer cells is unknown.
The tumor suppressor p53 gene is mutated in at 
least one-half of human cancers, and defects in the p53 
response pathway promote tumor development [13]. The 
functions of p53 influence the cell cycle, DNA repair, 
apoptosis, and nuclear vesicular trafficking in response to 
cellular stress such as DNA damage, oncogene activation, 
and hypoxia; however, the role of p53 in ER function is 
largely unknown [14, 15].
Here we demonstrate that p53 acts as an important 
regulator of ER function via suppression of the activation 
of the IRE1α/XBP1 pathway. Upon ER stress and 
homeostatic conditions, the splicing of XBP1 mRNA and 
the levels of XBP1(S) are stimulated in p53-deficient cells. 
Here we show that loss of p53 function induced IRE1α 
expression by inhibiting the p53-dependent association 
of IRE1α with synoviolin-1 (SYVN1) which induces 
degradation. Moreover, an IRE1α inhibitor STF-083010 
suppressed protein secretion, induction of cell death, and 
tumor growth in vivo in p53-deficient human tumor cells 
but not in those that expressed wild-type p53. Our findings 
reveal a novel mechanism for the regulation of IRE1α 
expression by p53. Thus, the regulation of the IRE1α/
XBP1 pathway by the p53–SYVN1–IRE1α complex 
represents a new mechanism for increasing ER function 
in cancer cells.
RESULTS
Loss of p53 function activates the IRE1α/XBP1 
pathway
To understand the role of p53 in the ER stress 
response mediated by the IRE1α/XBP1, ATF6, and 
PERK/eIF2α signaling pathways, we treated HCT116 
p53+/+ and HCT116 p53−/− cells (Figure 1A), MEF p53+/+ 
and MEF p53−/− cells (Figure 1B), and U2OS-shLuc 
and U2OS-shp53 cells (Figure 1C) with inducers of ER 
stress, brefeldin A (BFA), tunicamycin (Tm), or both, 
to determine the expression of proteins that mediate the 
ER stress response. p53 deficiency obviously affected 
IRE1α expression level compare to p90ATF6 cleavage 
(decreasing p90ATF6 expression) and phosphorylation of 
eIF2α by PERK upon ER stress (Figure 1A). Depletion 
or knockdown of p53 expression increased IRE1α and 
BiP expression in the absence of BFA and Tm treatments; 
furthermore, p53 deficiency enhanced the induction of 
IRE1α and BiP expression upon ER stress. During ER 
stress, active IRE1α splices XBP1 mRNA to generate 
XBP1(S) mRNA that encodes an active form of XBP1, 
XBP1(S), which initiates a major UPR program including 
the induction of ER chaperons such as BiP.[5] Therefore, 
we investigated whether the induction of IREα upon ER 
stress translated to downstream activation of XBP1 in p53-
deficient cell lines. Consistently, we observed enhanced 
XBP1 mRNA splicing and induction of XBP1(S) protein 
expression in p53-deficient cells in response to ER stress. 
Notably, basal IRE1α protein and spliced XBP1 mRNA 
levels were moderately elevated in the absence of ER 
stress agents, suggesting that not only does loss of p53 
function potentiates the IRE1α/XBP1 pathway of the UPR 
upon ER stress but p53 function may have an inhibitory 
effect on the pathway. Thus, increased BiP expression in 
p53-deficient cells was induced by increased XBP1(S) 
expression. These results suggest that p53 regulates 
IRE1α expression, and loss of p53 function induces 
IRE1α expression and activation of the IRE1α pathway, 
stimulation of XBP1 mRNA splicing, and XBP1(S) 
expression in the presence and absence of ER stress.
IRE1α expression is regulated by wild-type p53 
function
To support our hypothesis that loss of p53 function 
derepresses IRE1α expression, we analyzed nine wild-type 
p53- and 14 mutant p53-expressing human cancer cell 
lines to determine whether endogenous IRE1α expression 
levels were affected by p53 status. Western blot analysis 
showed that IRE1α was abundantly expressed in 12 out 
of 14 cells lines that expressed mutant p53: AU565, SK-
BR-3, HCC1937, SUM149, MDAMB231, MDAMB435, 
SNU1040, SW480, Calu3, EJ, T24, and RD (Figure 
2A). In contrast, the expression levels of IRE1α were 
significantly lower in cells that expressed wild-type p53. 
To corroborate these findings, we either knocked down 
p53 expression in wild-type p53 cells or overexpressed 
wild-type p53 in mutant p53 cells and measured IRE1α 
expression levels. Stable knockdown of p53 (shp53-
753 and shp53-814) in HCT116 p53+/+ and U2OS cells 
increased the levels of IRE1α compared with that of 
control cells (shLuc) (Figure 2B). Similarly, transient 
expression of wild-type p53 in HCT116 p53−/−, AU565, 
and SNU1040 cells decreased IRE1α expression (Figure 
2B). Furthermore, transient expression of several mutant 
p53 forms (p53-G245S, p53-R248W, p53-R249S, and 
p53-R273H), which lack DNA-binding and transactivation 
function, in p53-null H1299 human cancer cells had no 
effect on IRE1α expression; contrarily, only expression of 
wild-type p53 reduced IRE1α expression (Figure 2C). This 
suggests that wild-type p53 function negatively regulates 
IRE1α expression.
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p53 stimulates the degradation of IRE1α by the 
proteasome
To investigate the regulation of IRE1α expression 
by p53, we first looked at the effect of p53 on IRE1α 
mRNA expression. IRE1α mRNA levels were unchanged 
in HCT116 p53+/+ and HCT116 p53−/− cells (Figure 3A), 
suggesting that p53 may play a role in post-translational 
regulation of IRE1α protein stability. The stability of 
Figure 1: ER stress response in p53-deficient or knockdown cells. A. HCT116 p53+/+ or HCT116 p53−/− cells, B. MEF p53+/+ or 
MEF p53-/- cells, and C. U2OS shLuc or U2OS shp53 cells were incubated with Tm (0.5 µg/mL) or BFA (1 µg/mL) for the times indicated. 
Cell lysates were analyzed using western blotting with the indicated antibodies. The blot was cut based on the size of proteins or stripped. 
Total RNAs were extracted and subjected to RT-PCR analysis using specific primer sets for XBP1(U) and XBP1(S). Cell lysates were 
analyzed using western blotting with indicated antibodies.
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IRE1α protein was analyzed by Western blot analysis over 
a time course after addition of de novo protein synthesis 
inhibitor, cycloheximide, in HCT116 p53+/+ and HCT116 
p53−/− cells. IRE1α protein was degraded in HCT116 
p53+/+ cells (approximately 50% decrease at the endpoint), 
but the stability of IRE1α was significantly increased in 
HCT116 p53−/− cells (approximately 30% decrease at the 
endpoint) (Figure 3B). p53 protein was also degraded 
by cycloheximide in a time-dependent manner and 
this degradation affected the speed of IRE1α protein 
degradation in HCT116 p53+/+ cells: after cycloheximide 
treatment, IRE1α protein was rapidly degraded from 
0 hour to 2 hour in HCT116 p53+/+ cells, but IRE1α 
degradation rate was the same as HCT116 p53−/− cells 
from 2 hour to 8 hour) (Figure 3B). These results suggest 
that IRE1α expression is regulated by p53-dependent 
degradation.
The interaction of p53 with Synoviolin (SYVN1) 
stimulates SYVN1-IRE1α-dependent degradation 
of IRE1α
SYVN1 is an ER transmembrane E3 ubiquitin 
ligase and is directly associated with IRE1α to promote 
Figure 2: IRE1α expression is regulated by p53. A. Western blot analysis of the expression of endogenous IRE1α in 23 human 
cancer cell lines. Cell lines were grouped according to expression of wild-type or mutant p53 as indicated. (A well between wt-p53 and 
mutant-p53 cell lines was cut,  from the gel as indicated by a black line, due to the controversial p53 status of the cell line). Right panel: 
The intensities of the IRE1α bands (left panel) are expressed relative to those of β-actin. Values shown are the mean ± standard deviation 
(s.d.). The P value was calculated using two-way ANOVA. B. Downregulation of p53 expression induces increased expression of IRE1α. 
HCT116 p53+/+ and U2OS cells were transfected with shLuc, shp53 (753), or shp53 (814), and selected using puromycin. Whole cell 
lysates of a pool of transfectants were analyzed using western blotting with the indicated antibodies. C. Overexpression of wild-type p53 
inhibits IRE1α expression in mutant-p53 cell lines. Cell lysates, prepared 48 h after transfection with wild-type p53, were analyzed for the 
expression of indicated proteins. D. Mutant p53 proteins do not inhibit IRE1α expression. Cell lysates were prepared from cells transfected 
with p53-G245S, p53-R248W, p53-249S, and p53-R273H expression vectors or from cells that constitutively expressed wild-type p53 and 
were analyzed for the expression of the indicated proteins.
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the ubiquitination and proteasomal degradation of IRE1α 
[16]. Therefore, we asked whether p53 regulates this 
process. When SYVN1 expression was inhibited by 
transfecting HCT116 p53+/+ cells with SYNV1 siRNA, 
IRE1α expression increased (Figure 4A). In contrast, 
only a minor increase in IRE1α expression was observed 
in HCT116 p53−/− cells transfected with SYNV1 siRNA. 
Furthermore, the levels of SYVN1 were not altered by the 
presence or absence of p53. Next, we performed reciprocal 
immunoprecipitation experiments to determine whether 
p53 expression affects the association between SYVN1 
and IRE1α in HCT116 p53+/+ and HCT116 p53−/− cells. 
We detected an association between endogenous SYVN1 
and IRE1α in HCT116 p53+/+ cells, and this association 
was suppressed in HCT116 p53−/− cells (Figure 4B). These 
results suggest that p53 expression may stimulate the 
association between SYVN1 and IRE1α.
Next, we examined whether wild-type p53 directly 
interacts with SYVN1–IRE1α complex. Wild-type 
p53 and two p53 mutants (R249S and R273H) were 
overexpressed in p53-null H1299 cells and subjected 
to coimmunoprecipitation analysis using an anti-p53 
primary antibody. The wild-type but not mutant forms 
of p53 immunoprecipitated with SYVN1 (Figure 4C). 
Furthermore, wild-type and mutant forms of p53 did 
not directly associate with IRE1α. Based on these 
results, p53–SYVN1–IRE1α complex may exist but is 
undetectable due to possible rapid degradation of IRE1α 
by the proteasome. Thus, we investigated whether p53–
SYVN1–IRE1α complex could be detected by inhibition 
of the proteasome function. Wild-type p53 overexpressed 
p53-null H1299 cells or HCT116 p53+/+ cells were treated 
with the proteasome inhibitor MG132 and subjected to 
coimmunoprecipitation analysis using an anti-p53 primary 
antibody. Pretreatment with the proteasome inhibitor 
MG132 increased IRE1α expression and enabled the 
detection of the p53-SYVN1-IRE1α complex (Figure 4D). 
However, p53–SYVN1–IRE1α complex was not observed 
in the absence of MG132, indicating that this complex 
is likely to be disrupted by the proteasome-mediated 
degradation. Collectively, these results suggest that wild-
type p53, SYVN1 and IRE1α form a triple complex and 
IRE1α is subsequently degraded by the proteasome. Thus, 
loss of p53 function disrupts the regulation of IRE1α by 
Figure 3: p53 stimulates IRE1α protein degradation. A. The level of p53 did not affect the expression of IRE1α mRNA. Total RNAs 
were extracted and subjected to qRT-PCR analysis using specific primer sets for IRE1α, p53, and GAPDH, and the data were normalized 
to those of GAPDH. Data shown are the mean ± s.d. (triplicates measured at the same time). B. p53 promotes IRE1α degradation. The 
indicated cells were treated with cycloheximide (25 µg/mL) for 1 h and incubated further for the indicated times. Cell lysates were analyzed 
for the expression of the indicated proteins. The blot was cut based on the size of the proteins of interest (left panel). The intensities of the 
IRE1α bands were determined (one of the gels is shown in left panel) and are expressed relative to those of β-actin (right panel). Values 
shown are the mean ± s.d. of three independent experiments. 
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SYVN1, and as a result, protects IRE1α from proteasomal 
degradation and elevates IRE1α protein expression.
The secretory function of ER is inhibited in cells 
expressing wild-type p53 in an IRE1α-dependent 
manner
The IRE1α/XBP1 pathway is critical for the 
secretory function of ER [8, 18]. Since we’ve shown 
that the loss of p53 function activates the IRE1α/XBP1 
pathway, we next investigated the effect of p53 on 
the secretory output of ER using the secreted alkaline 
phosphatase (SEAP) assay [19]. We expressed SEAP in 
HCT116 p53+/+ and HCT116 p53−/− cells and monitored 
its secretion. Overexpression of SEAP induced a 
weak ER stress response, which was indicated by the 
expression of BiP and P-eIF2α (data not shown). Loss 
of p53 function significantly enhanced secretion of 
SEAP by approximately 2-fold compared with control 
cells (Figures 5A and S1C). Furthermore, we examined 
whether the increased ER function, as seen from increased 
SEAP activity, is due to increased ER mass and capacity. 
Immunofluorescence microscopy demonstrated that 
DsRed proteins labeled with KDEL ER localization motif 
were more widely distributed throughout the cytoplasm 
of HCT116 p53−/− cells than the HCT116 p53+/+cells; 
this is consistent with an increase in ER mass (Figure 
S3). Next, we examined the effect of forced expression 
of mutant forms (p53-G245S, p53-R248W, p53-R249S, 
and p53-R273H) or wild-type p53 on SEAP activity in 
p53-null H1299 human cancer cells. Expression of the 
p53 mutants inhibited secretion of SEAP to a lesser extent 
than that of wild-type p53 (Figure 5B). To determine if 
p53 contributes to ER function through the IRE1α/XBP1 
pathway, secretion of SEAP in HCT116 p53−/− cells was 
measured under siRNA knockdown of ATF6, PERK, or 
IRE1α. Inhibition of SEAP secretion was only seen in 
siIRE1α (Figure 5C). Together, these findings suggest that 
the secretory function of ER was enhanced by loss of p53 
function through the IRE1α/XBP1 pathway.
Figure 4: Synoviolin promotes IRE1α degradation in a wild-type p53-dependent manner. A. SYVN1 suppresses IRE1α 
protein expression in wild-type p53 cells. HCT116 p53+/+ or HCT116 p53−/− cells were transfected with siControl (−) or siSYVN1 (+) 
and cultured for 24 h. Cell lysates were analyzed using western blotting with indicated the antibodies (left panel). The intensities of the 
SYVN1 bands were quantified. The levels of SYVN1 are reported relative to those of β-actin (right panel). The blot was cut based on the 
size of proteins or stripped and reprobed. B. IRE1α and SYVN1 interaction is suppressed in p53-deficient cells. Proteins were cross-linked 
with DSP before protein extraction. Coimmunoprecipitation was performed with cell lysate using an IRE1α or an SYVN1 antibody. C. 
SYVN1 interacts with wild-type p53. H1299 cells transiently expressed wild-type p53, p53-R248S, or p53-R273H. Coimmunoprecipitation 
experiments were performed using the anti-p53 antibody. D. p53-SYVN1-IRE1α complex is observed by treatment with proteasome 
inhibitor. H1299 cells transiently expressing wild-type p53 (left panel) or HCT116 p53+/+ (right panel) cells were treated with 50 µM 
MG132 for 3 h. Coimmunoprecipitation experiments were performed using the anti-p53 antibody.
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IRE1 inhibitor STF-083010 limits the growth of 
p53-deficient cells in vivo
We observed that loss of p53 function significantly 
increased the secretory function of ER by activating the 
IRE1α/XBP1 pathway. Therefore, we hypothesized that 
activation of the IRE1α/XBP1 pathway by the loss of 
p53 function imparts an ER stress resistant phenotype to 
cancer cells with p53 mutations. To test this hypothesis, 
we evaluated whether inhibiting the IRE1α/XBP1 pathway 
using the IRE1 inhibitor STF-083010 would effectively 
inhibit the ability of p53-deficient cancer cells to proliferate 
and secrete SEAP. The inhibition of IRE1α was confirmed 
by XBP1(S) expression (Figure S2A). Treatment with 
STF-083010 reduced the viability of HCT116 p53−/− cells 
by approximately 20% compared with that of HCT116 
p53+/+ cells (Figure 6A). Furthermore, HCT116 p53−/− 
Figure 5: p53 deficiency increases secretory the function of the ER through the IRE1α/XBP1 pathway. A. HCT116 
p53+/+ or HCT116 p53−/− cells, MEF p53+/+ or MEF p53-/- cells, and U2OS shLuc or U2OS shp53 cells expressing secreted embryonic 
alkaline phosphatase (SEAP) were transduced with a pSEAP2 control vector and washed 24 h after transduction. The medium was then 
changed, and the cells were cultured for another 6 h. Culture media were analyzed for SEAP activity, and luminescence was normalized to 
cell number. The transfection efficiencies of HCT116 p53+/+ and HCT116 p53−/− cells were approximately 80% each (data not shown). B. 
Overexpression of wild-type p53 inhibited SEAP activity. SEAP activities of cells that constitutively expressed the indicated p53 molecules 
were analyzed using the same procedure described in (A). C. HCT116 p53−/− cells that expressed SEAP were transfected with siControl, 
siATF6, siPERK, or siIRE1α, cultured for 24 h, and following a change of medium, the cells were cultured for another 6 h. Whole cell 
lysates were analyzed using western blotting with the indicated antibodies, and culture supernatants were analyzed for SEAP activity. 
Values shown are the mean ± s.d. of three different experiments simultaneously measured. The P value was calculated using two-way 
ANOVA.
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cells resisted ER stress-induced cell death compared with 
that of HCT116 p53+/+ cells, but simultaneous treatment 
with STF-083010 abolished the resistance. Similar results 
were obtained using MEF p53+/+ and MEF p53−/− cells 
and U2OS-shLuc and U2OS-shp53 cells. To determine 
the effect of STF-083010 on the secretory output of 
ER, SEAP activity was measured in HCT116 p53+/+ and 
HCT116 p53−/− cells treated with DMSO or STF-083010. 
SEAP activity was clearly suppressed in HCT116 p53−/− 
cells treated with STF-083010 (Figure S2B), showing 
that inhibition of the IRE1α/XBP1 pathway abrogates 
the increased ER function from the loss of p53 function. 
Together, this suggests that activation of the IRE1α/XBP1 
pathway in cancer cells with loss of p53 function promotes 
ER stress resistant phenotype.
To further determine whether inhibition of the 
IRE1α/XBP1 pathway in p53-deficient cells suppresses 
tumor growth, mice were engrafted with HCT116 
p53+/+ and HCT116 p53−/− cells, and the effect of STF-
083010 on tumor growth was observed. Tumors induced 
by HCT116 p53−/− cells aggressively grew compared 
with those induced by HCT116 p53+/+ cells. However, 
administration of STF-083010 to tumors induced by 
HCT116 p53−/− cells significantly reduced tumor volume 
and weight by 75% and 73% at the endpoint, respectively 
(Figure 6B). In contrast, the respective values for STF-
083010-treated HCT116 p53+/+ cells did not significantly 
differ (approximately 32% and 28%). Thus, the antitumor 
effect of STF-083010 was limited to p53-deficient tumors. 
Together, these data suggest that the malignant phenotype 
of p53-deficient tumors may be attributed to activation of 
the IRE1α/XBP1 pathway.
Figure 6: The IRE1α inhibitor (STF-083010) suppresses the growth in vitro and in vivo of p53-deficient human cancer 
cells. A. Effects of an IRE1α inhibitor on cell viability and on Tm-induced cell death in p53-deficient cells. HCT116 p53+/+ or HCT116 
p53−/− cells, MEF p53+/+ or MEF p53-/- cells, and U2OS shLuc or U2OS shp53 cells were treated with Tm (0.5 mg/mL), STF-083010 (50 
µM), or both for 24 h. Cell viability was determined using an MTT assay. Values shown are the mean ± s.d. of three different experiments 
measured simultaneously. B. An IRE1α inhibitor selectively suppresses the growth of p53-deficient tumors in nude mice. HCT116 p53+/+ 
and HCT116 p53−/− cells were used to engraft nude mice, and 4 days after injecting the cells, DMSO or STF-083010 (40 mg/kg) was 
intraperitoneally administered once every 3 days. Tumor volume was measured on the indicated days. After 15 days, the weights of the 
tumors (left panel) were measured. Values shown are the mean ± standard error of the mean of eight mice from each group. The P value 
was calculated using two-way ANOVA.
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DISCUSSION
We report here the discovery that the IRE1α/
XBP1 pathway is regulated by p53. We show that loss 
of p53 function enhanced the secretory function of ER 
and suppressed ER stress-mediated cell death through 
activation of the IRE1α/XBP1 pathway. Furthermore, 
we show that the interaction between wild-type p53 and 
SYVN1 enhanced the association of SYVN1 and IRE1α, 
which is critical for proteasome-dependent degradation of 
IRE1α.
ER membrane protein homeostasis is controlled by 
ER-associated degradation (ERAD) [20]. In general, a 
misfolded or unfolded protein is detected by an adaptor 
protein, such as an ER chaperon, and is ubiquitinated 
by E3 ubiquitin ligase, and the ubiquitinated protein 
is transported from ER to the cytosol and degraded by 
the proteasome [20]. Recent studies report that ERAD 
is involved in the turnover of several proteins, but the 
mechanism is unclear [21, 22]. SYVN1 promotes the 
ubiquitination and degradation of IRE1α; however, the 
mechanism of regulation of the interaction between 
SYVN1 and IRE1α is undetermined [16]. In the present 
study, we discovered that p53 is a key factor that 
stimulates the association of SYVN1–IRE1α through its 
interaction with SYVN1, indicating that the p53–SYVN1–
IRE1α complex effectively utilizes IRE1α as a substrate. 
These results provide a new insight into the regulation of 
homeostatic protein expression by ERAD.
The accumulating evidence clearly indicates that 
increasing ER function through UPR, particularly through 
the IRE1α/XBP1 pathway, is critical for oncogenesis 
by adapting tumor cells to ER stress and the secretion 
of growth factors [6, 10, 12]. However, the regulatory 
mechanism of the activation of the IRE1α/XBP1 pathway 
was not identified by these studies. We also showed that 
cancer cell lines expressing mutant forms of p53 expressed 
high levels of IRE1α. Furthermore, XBP1(S) expression 
was induced in these cells in the absence of stress. 
Therefore, our data suggest that p53 is a crucial regulator 
for ER function, and loss of p53 function induced 
upregulation of IRE1α expression, which increases ER 
function. In p53 deficient cells, while the IRE1α/XBP1 
pathway was upregulated, ER stress dependent activation 
of ATF6 and PERK/eIF2α pathway was suppressed. These 
results are consistent with a previous study, where p53 
deficiency suppressed the phosphorylation of eIF2α by 
zebularine induced ER stress [23]. It has been previously 
reported that overexpression of BiP suppresses PERK and 
ATF6 activation, subsequently becoming resistant to ER 
stress [24-26]. Thus, upregulation of BiP by activation 
of IRE1α/XBP1 pathway in the absence of stress may 
suppress activation of ATF6 and PERK/eIF2α pathway 
by ER stress in p53 deficient cells. Further ER stress 
transactivates proapoptotic p53-target genes, such as 
PUMA and NOXA, which is implicated in the induction 
of cell death during ER stress [27]. Thus, this pathway 
is involved in the loss of p53-mediated resistance to ER 
stress-induced cell death. Together, these data suggest that 
wild-type p53 suppresses ER function, and the adaptation 
to ER stress by downregulating IRE1α expression is a 
consequence of the tumor suppressor activity of p53.
An important aspect of the present study is the 
demonstration that an IRE1 inhibitor STF-083010 
selectively inhibited the growth of tumors induced by 
p53-null human cancer cells in nude mice, suggesting that 
IRE1 inhibitors may serve as anticancer drugs that target 
mutant forms of p53. Cancer cells with p53 mutations 
are highly malignant and aggressive, and activation of 
the IRE1α/XBP1 pathway contributes to this malignant 
phenotype [28, 29]. DNA damaging agents are widely used 
to treat various types of cancer, and their efficacy depends 
on the tumor suppressor activity of wild-type p53 [28, 
30]. Thus, cancer cells that express mutant forms of p53 
are resistant to numerous conventional anticancer agents. 
Furthermore, such cancers are characterized by more 
aggressive phenotypes. Our data support the conclusion 
that activation of the IRE1α/XBP1 pathway contributes 
to this phenotype in cancers that express mutant forms 
of p53. Therefore, inhibiting the activation of the IRE1α/
XBP1 pathway may represent a promising new modality 
for treating cancers that lack p53 function. Taken together, 
our data reveal a previously unidentified mechanism 
mediated by p53 that maintains ER function through the 
regulation of the activation of the IRE1α/XBP1 pathway 
by SYVN1-dependent proteasomal degradation of IRE1α.
MATERIALS AND METHODS
Xenograft model
The Animal Research Committee of Kochi Medical 
School approved all experimental protocols and surgical 
procedures (Permit Number: H-00023). Each BALB/c 
nude mouse (male, 5 weeks of age) was subcutaneously 
inoculated in the right and left hind footpads with 5 × 106 
HCT116 p53+/+ or HCT116 p53−/− cells. Four days later, 
DMSO or STF-083010 (40 mg/kg) was intraperitoneally 
administrated every 3 days. Tumors were measured every 
5 days, and their volumes were calculated using the 
equation mm3 = (length (mm)) × (width (mm))2/2).
Cell lines and generation of stably transfected cell 
lines
U2OS, H1299, HCT116 p53+/+, HCT116 p53−/−, 
HT1080, ME-180, A549, A172, Calu3, LS174T, 
MDAMB468, SK-BR-3, HCC1937, MDAMB435, 
MDAMB231, AU565, SUM149, WiDr, SNU1040, 
SW480, EJ, T24, and RD cells were maintained in DMEM 
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supplemented with 10% FBS, 100 U/mL penicillin, and 
100 µg/mL streptomycin. MEF p53+/+ and MEF p53−/− 
cells were maintained in DMEM supplemented with 10% 
FBS, 1 % NAEE and 0.5 % 2-mercaptoethanol. All cells 
were maintained at 37°C in an atmosphere containing 
5% CO2. Wild-type p53, p53-G245S, p53-R248W, p53-
R249S, p53-R273H, shp53 (pLKO.1 p53 shRNA-753 
and -814 from Sigma-Aldrich (TRCN0000003753)), 
and shLuc (pLKO.1 Luciferase shRNA Control, Sigma-
Aldrich) constructs were introduced into HCT116 
p53+/+, U2OS, or H1299 cells using lipofection. Cells 
transfected with these plasmids were selected using G418 
or puromycin for 2 weeks. Experiments were performed 
using stable, pooled clones. HCT116 p53−/−, H1299, 
AU565, and SNU1040 cells were transiently transfected 
using lipofection with plasmids that expressed wild-type 
p53, p53-R249S, or p53-R273H.
SEAP assay
Cells were transduced with the pSEAP2-Control 
Vector (Clontech). The cells were washed 24 h after 
transfection, transferred to plates containing fresh media, 
and then cultured for 2 h. Culture supernatants were 
harvested and assayed for SEAP activity using the Great 
EscAPe SEAP Reporter System (Clontech) [19].
Immunoprecipitation
Cells were washed with PBS and incubated with 
or without PBS containing 1 mM dithiobis [succinimidyl 
propionate] (DSP) for 30 min, and the reaction was 
quenched by adding 50 mM Tris (pH 8.0) for 3 min. Cells 
were lysed in Tris lysis buffer (50 mM Tris-HCl (pH 7.4), 
1 mM EDTA, 1 % Triton-X, 1 mM NaF, protease inhibitor 
mix (Nakarai), and incubated on ice for 15 min. Cellular 
debris was pelleted by centrifugation at 14,000 rpm for 
10 min at 4°C. Primary antibody was covalently linked to 
protein A/G plus-agarose or protein A/G magnetic beads. 
Immunoprecipitated products were incubated with LDS 
sample buffer containing 50 mM DTT at 95°C for 10 min.
Immunoblotting analysis
Immunoblotting experiments were conducted 
as previously described [31]. Antibodies used for 
immunoblotting were specific for the proteins as follows: 
BiP, P-eIF2α, eIF2α, PARP, Synoviolin1, PERK, and 
IRE1α (Cell Signaling); GADD34, P-PERK, XBP1, 
ATF6, MDM2, and p53 (Santa Cruz); and β-actin (Sigma). 
Antibodies were diluted to 1:1000, except for anti-β-actin 
(1:10000). Secondary antibodies were purchased from 
Promega (antirabbit and antimouse at 1:5000) or Rockland 
(TrueBlot antimouse at 1:1000).
Real-time quantitative PCR and RT-PCR
Real-time quantitative PCR (qRT-PCR) and RT-
PCR were conducted as previously described [31]. To 
normalize the amount of total RNA present in each 
reaction, GAPDH cDNA served as an internal standard. 
The primers used were (name: forward primer & reverse 
primer): IRE1α: 5′-TCAAACCTCATGGGTTCTCC-3′ 
and 5′-GTGTCATCCAACGTGGTCAG-3′; GAPDH: 
5′-CTCAGACACCATGGGGAAGGTGA-3′ 
and 5′-ATGATCTTGAGGCTGTTGTCATA-3′: 
p53: 5′-AGAGTCTATAGGCCCACCCC-3′ and 
5′-GCTCGACGCTAGGATCTGAC-3′. The cDNAs 
were used in RT-PCR to detect spliced and non-
spliced forms of XBP1 mRNA. The primers used were 
(name: forward primer and reverse primer): XBP1: 
5′-GGAGTTAAGACAGCGCTTGGGGA-3′ and 
5′-TGTTCTGGAGGGGTGACAACTGGG-3′.
Immunofluorescence analysis
HCT116 p53+/+ and HCT116 p53−/− cells were 
stably transfected with KDEL-DsRed2 (Clontech: 
pDsRed-ER vector), and treated cells were fixed in 4% 
paraformaldehyde for 15 min at room temperature. Cells 
were then extensively washed to remove any debris. 
All images were acquired using an Olympus confocal 
microscope and processed using Adobe Photoshop 
software.
Cell viability assays
Cell viability was determined using the MTT 
method [32]. After treatment with Tm, STF-083010, or 
both, cells were incubated with MTT solution (1 mg/
mL) for 2 h. Isopropanol and HCl were added to the 
final concentrations of 50% and 20 mM, respectively. 
The optical density at 570 nm was determined using a 
spectrophotometer using a reference wavelength of 630 
nm.
siRNA experiments
U2OS cells were transfected with an siRNA 
specific for synoviolin[33] (ON-TARGETplus siRNA, 
Dharmacon), ATF6, PERK, IRE1α (functionally 
validated siRNAs from Qiagen) and Control (Santa 
Cruz) [31] at final concentrations of 50 nM, using 
X-tremeGENE transfection reagent (Roche) according to 
the manufacturer’s instructions.
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Statistical analysis
Differences between mean values were evaluated 
using two-way ANOVA followed by Tukey’s test or 
the Student t test for unpaired results of more than two 
experimental groups. Differences were considered 
statistically significant for P < 0.05.
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